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Introduction
Breast cancer is the most common cancer worldwide and 
the second most common leading cause of cancer related 
death among women. Although incidence is generally 
lower in Asia, it is still the most prevalent female cancer 
in this part of the world. It is estimated that at least 60% 
of the world’s 7 billion people are Asians and in particular 
the fast growing trend of breast cancer incidence in Asia 
especially China and India where the population is large can 
impose significant health burden to the society (1). There 
is an estimated 1.67 million new cases of breast cancer 
diagnosed in 2012 worldwide and 39% of these are found 
in Asia (Globocan 2012, http://globocan.iarc.fr/Pages/fact_
sheets_cancer.aspx). There is increasing knowledge that 
a proportion of breast cancer are due to the inheritance 
of mutations in two susceptibility high penetrant genes, 
BRCA1 and BRCA2 (2). Women who carry such genetic 
alterations in BRCA1 and BRCA2 genes has four to five fold 
increased lifetime risk of developing breast cancer by the 
age of 70 years compared to general population (45–85% 
vs. 12.5%) (3). Although most studies on BRCA mutations 
have been performed in Caucasian or Ashkenazi Jewish 
cohorts, there are increasing literatures published over the 
past few years where individual Asian countries have similar 
frequencies of BRCA1/2 mutations in clinically high risk 
cohorts which have been tested (4).
Moreover, for decades, the use of PCR based Sanger 
Sequencing and additional methodology such as multiplex 
ligation-dependent probe amplification (MLPA) has been 
the gold standard technique in identifying germline and 
hotspots mutations (5). With the advent of advanced 
technology, next-generation sequencing (NGS) based 
on clonal amplifications coupled with massively parallel 
sequencing has become more commonly used. This allows 
the investigation of multiple genes at a lower cost and 
a faster turnover time (5-7) and facilitates the testing of 
additional gene mutations both in the germline and somatic 
setting, hence a huge influx of multigene panels testing 
has become available both in the commercial setting and 
academic setting (7-10).
With the increase awareness and knowledge of hereditary 
breast and ovarian cancer (HBOC), i.e., reduction of 
cost, turnover time and availability of genetic testing, it 
is inevitable that genetic testing will have an increase role 
in Asia. However, the implementation of any health care 
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options less known ethnic cohort may require adaptations 
and adjustments to established guidelines set for use in 
Western countries. 
The selections for genetic testing of individuals are fairly 
well defined in Western countries. For mutations such as 
BRCA1 and BRCA2 mutations or even other high penetrant 
genes, selection of individuals for genetic testing are mainly 
based on age of onset of breast or ovarian cancer, the extend 
of family history of related cancers, and also subtype of 
cancers, for example triple negative breast cancer for BRCA 
mutations. 
The most well established guidelines would be that 
of National Comprehensive Cancer Network (NCCN) 
Version 2.2016 (Table 1). Apart from the clinical indications 
based on cancer history, a number of genetic risk prediction 
models have been established, [such as BOADICEA, 
BRCAPRO, Myriad, Couch (also known as PENN), 
Shattuck-Eidens and Manchester (11-16)] that can assess 
Table 1 Hereditary breast and/or ovarian cancer syndrome testing criteria (adapted from NCCN Guidelines Version 2.2016)
Individual from a family with a known deleterious (pathogenic variant) BRCA1/BRCA2 gene mutation
Personal history of breast cancer + one or more of the followings:
Diagnosed ≤45 y
Diagnosed ≤50 y with:
An additional breast cancer primary
≥1 close blood relative with breast cancer at any age
≥1 close relative with pancreatic cancer
≥1 relative with prostate cancer (Gleason score ≥7)
An unknown or limited family history
Diagnosed ≤60 y with a:
Triple negative breast cancer
Diagnosed at any age with:
≥1 close blood relative with breast cancer diagnosed ≤50 y
≥2 close blood relatives with breast cancer at any age
≥1 close blood relative with ovarian carcinoma
≥2 close blood relatives with pancreatic cancer and/or prostate cancer (Gleason score ≥7) at any age
A close male blood relative with breast cancer
For an individual of ethnicity associated with higher mutation frequency (e.g., Ashkenazi Jewish) no additional family history may be 
required
Personal history of ovarian carcinoma
Personal history of male breast cancer
Personal history of pancreatic cancer or prostate cancer (Gleason score ≥7) at any age with ≥1 close blood relative with ovarian carcinoma 
at any age or breast cancer ≤50 y or two relatives with breast, pancreatic or prostate cancer (Gleason score ≥7) at any age
Personal history of pancreatic cancer and Ashkenazi Jewish ancestry
Family history only
First- or second-degree blood relative meeting any of the above criteria
Third-degree blood relative with breast cancer and/or ovarian carcinoma with ≥2 close blood relatives with breast cancer (at least one 
with breast cancer ≤50 y) and/or ovarian carcinoma
NCCN, National Comprehensive Cancer Network.
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the pre-test probability of identifying a BRCA1 or BRCA2 
mutation and enable efficient targeting of genetic testing. 
However these models are mainly designed based on non-
Asian cohorts and a number of Asian countries have found 
the variability of the accuracy in using these models on 
Asian cohorts leading to the development of Asian based 
models such as KOHCal which is at present being validated 
on other Asia cohorts and aims to increase the accuracy of 
selection of appropriate probands for genetic testing (17). 
Most Asian countries however would base their selection of 
probands by clinical criteria (4).
The management of mutation carriers particularly for 
BRCA mutations is also very well established and for the 
past two decades emphasis have been on both primary 
and second prevention, namely screening to achieve early 
diagnosis or aiming for risk reduction using surgery or 
medication. For the breasts, mutation carriers for BRCA 
mutations are usually offered alternate screening options 
including the choice of intensive breast surveillance (18) 
(MRI breasts in addition to standard breast imaging such 
as mammography and ultrasonography), and preventative 
interventions including the consideration of mastectomy 
instead of breast conservation surgery due to the increased 
risk of contralateral breast cancer and the likelihood of 
increase second primary cancers in the ipsilateral breast 
in the setting where the individual have already had 
breast cancer. For risk reduction, options of prophylactic 
mastectomy and salpingo-oophorectomy, or the prescription 
of chemoprevention drugs are the main choices. The 
indications of BRCA mutation testing have become more 
popularized recently as new data have supported the 
options of selection of therapeutic management of breast 
and ovarian cancers based on BRCA mutation status such 
as the choice of chemotherapy as primary treatments such 
as the use of carboplatin as a neoadjuvant agent and the 
evolvement of the use of targeted therapies, such as PARP 
inhibitors.
However the uptake rate and choice of management 
in Asia is much dependent on the availability of screening 
options and MRI are less likely performed in most Asian 
countries due to lack of resource or availability. Prophylactic 
surgeries are offered but uptake rates of RRM are much less 
compared to United States (1).
Genetic counselling plays an important role in selection 
of individuals suitable for genetic testing, collecting 
an accurate family pedigree and to explain the process, 
advantages and disadvantages of genetic testing and its 
implication not only to the individual but also the family 
members. Traditional counselling takes a long period of 
explanation on an individual face to face basis. A genetic 
counselling requires a 1−2 years training in Western 
Universities in general but in Asia there is a lack of training 
for genetic counselling aside from larger countries such 
as Japan and Korea where there are national and regional 
training programmes for genetic counsellors (19,20). For 
most other countries genetic counsellor are usually nurses, 
psychologist or other allied health workers with certification 
training in cancer genetics from long distance certification 
courses or trained by the genetic specialist in the clinical 
setting locally. With the increase indications for genetic 
testing, it is likely that like the West, the Asian model of 
counselling may also have to change base on the needs and 
local adaptation. The develop of the best implementation 
of counselling flow will need to be addressed be it the 
choice of traditional counselling, or newer models using 
telephone counselling, streamlining other specialties such 
as oncologist based initial counselling but yet avoiding the 
misinterpretation of the genetic result and compromising 
care, would be of utmost importance.
It has also been established that although the prevalence 
of mutations in genes such as BRCA genes are likely to 
be similar among different ethnicities, based on studies 
on BRCA mutations in Asian population to date, there 
is a discrepancy between the percentages of BRCA1 and 
BRCA2 mutation carriers, and there is more likelihood of 
detecting gene mutations which have not been reported 
(Novel) or are variant of uncertain significance (VUS) (4). 
It is likely that as genetic testing gets more popularized, 
the VUS and novel mutation rates will decrease as we get 
to better understand our cohorts. The characterization of 
VUS pathogenicity can be based on different algorithms 
in different laboratories and centers and streamlining this 
particularly in Asia where there is still a comparative higher 
rate of detection of such VUS will aid the implementation 
of appropriate management of these families (21). Apart 
from BRCA mutations, the inevitable use of gene panels to 
personalize care for individuals based on genetics would 
create a forward management options for families at risk. 
However, the validation and research work on these panels 
are warranted and is important based on the experience on 
BRCA testing for use of the panels in ethnicities such as 
Asians, which to date are still relatively unknown in their 
world of genetic testing for alternative genes other than 
BRCA genes.
Apart from the biology of genetic testing, practical issues 
such as genetic discrimination and cost of testing is still 
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an imminent issue which would have to be confronted in 
Asia. Unlike the West, genetic testing is not covered by 
insurance nor government funds in Asia in general and 
most centers have obtained its resources for testing through 
research grants and philanthropy as an academic research 
project (19). Moreover there is no Genetic Information 
Non-discrimination act similar to that of United States (22) 
in most countries in Asia, hence unless this is addressed 
formally, there may be deterrent for genetic testing. 
As genetic testing is gradually becoming an integral part 
of cancer care and to some, even considered as standard of 
care, for countries such as Asia where genetic testing and 
management for hereditary cancers are still comparatively 
at its infancy compared to the West, more attention should 
be given to performing research in this area and also 
implementation of a good supporting system in order to 
benefit more cancer patients and their families. 
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